Regional Hepatic Chemotherapies in the Treatment of Colorectal Cancer Metastases to the Liver

Seminars in Oncology

Volumn 37, Issue 2, 2010, Pages 149-159

  Pwint, Thinn P ^a   Midgley, Rachel ^a   Kerr, David J ^b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DEXAMETHASONE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HEPARIN; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BILIARY SCLEROSIS; BILIARY TRACT DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CATHETER COMPLICATION; CATHETER DISPLACEMENT; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEVER; GASTRITIS; HEMATOMA; HEPATIC ARTERY; HEPATIC ARTERY THROMBOSIS; HEPATITIS; HUMAN; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER PERFUSION; LIVER SURGERY; MICROWAVE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PEPTIC ULCER; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SCLEROSIS; SELECTIVE INTERNAL RADIATION THERAPY; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77952343707     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.03.005     Document Type: Article

References (75)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Center M.M., Jemal A., and Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18 (2009) 1688-1694
3. Nordlinger B., Van Cutsem E., Rougier P., et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer?. A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43 (2007) 2037-2045
4. Scheele J., Altendorf-Hofmann A., Grube T., Hohenberger W., Stangl R., and Schmidt K. Resection of colorectal liver metastases. What prognostic factors determine patient selection?. Chirurg 72 (2001) 547-560
5. Scheele J., Stang R., Altendorf-Hofmann A., and Paul M. Resection of colorectal liver metastases. World J Surg 19 (1995) 59-71
6. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14 Suppl 2 (2003) ii13-ii16
7. Hughes K.S., Simon R., Songhorabodi S., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100 (1986) 278-284
8. Scheele J., Stangl R., and Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77 (1990) 1241-1246
9. Stangl R., Altendorf-Hofmann A., Charnley R.M., and Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 343 (1994) 1405-1410
10. Ensminger W.D., Rosowsky A., Raso V., et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 38 (1978) 3784-3792
11. Wolmark N., Rockette H., Wickerham D.L., et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 8 (1990) 1466-1475
12. Taylor I., Machin D., Mullee M., Trotter G., Cooke T., and West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 72 (1985) 359-363
13. Laffer U., Metzger U., Aeberhard P., et al. Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. Int J Colorectal Dis 23 (2008) 1233-1241
14. Rougier P., Sahmoud T., Nitti D., et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Lancet 351 (1998) 1677-1681
15. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345 (1995) 349-353
16. James R.D., Donaldson D., Gray R., Northover J.M., Stenning S.P., and Taylor I. Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 90 (2003) 1200-1212
17. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 89 (1997) 497-505
18. Labianca R., Boffi L., Marsoni S., Banducci S., et al. A randomised trial of intraportal (IP) versus systemic (SY) versus IP + SY adjuvant chemotherapy in patients with resected Dukes B-C colon carcinoma [abstract]. Proc Am Soc Clin Oncol 18 (1999) 1014
19. Labianca R., Fossati R., Zaniboni A., et al. Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst 96 (2004) 750-758
20. Kemeny N., and Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 2 (2001) 418-428
21. Kemeny N., Seiter K., Niedzwiecki D., et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69 (1992) 327-334
22. Hohn D.C., Stagg R.J., Friedman M.A., et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7 (1989) 1646-1654
23. Chang A.E., Schneider P.D., Sugarbaker P.H., Simpson C., Culnane M., and Steinberg S.M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206 (1987) 685-693
24. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8 (1990) 1885-1893
25. Martin Jr. J.K., O'Connell M.J., Wieand H.S., et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125 (1990) 1022-1027
26. Rougier P., Laplanche A., Huguier M., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10 (1992) 1112-1118
27. Lorenz M., and Muller H.H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18 (2000) 243-254
28. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361 (2003) 368-373
29. Kemeny N., Daly J., Reichman B., Geller N., Botet J., and Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107 (1987) 459-465
30. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24 (2006) 1395-1403
31. Mocellin S., Pilati P., Lise M., and Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 25 (2007) 5649-5654
32. Mocellin S., Pasquali S., and Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev (2009) CD007823
33. Kemeny N., Gonen M., Sullivan D., et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19 (2001) 2687-2695
34. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23 (2005) 4888-4896
35. Shitara K., Munakata M., Kudo T., et al. Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer. Gan To Kagaku Ryoho 33 (2006) 2033-2037
36. Gallagher D.J., Capanu M., Raggio G., and Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 18 (2007) 1995-1999
37. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27 (2009) 3465-3471
38. Lygidakis N.J., Ziras N., and Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42 (1995) 155-161
39. Lorenz M., Muller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228 (1998) 756-762
40. Kemeny M.M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20 (2002) 1499-1505
41. Tono T., Hasuike Y., Ohzato H., Takatsuka Y., and Kikkawa N. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer 88 (2000) 1549-1556
42. Rudroff C., Altendorf-Hoffmann A., Stangl R., and Scheele J. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 384 (1999) 243-249
43. Kusunoki M., Yanagi H., Noda M., Yoshikawa R., and Yamamura T. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89 (2000) 1228-1235
44. Clancy T.E., Dixon E., Perlis R., Sutherland F.R., and Zinner M.J. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg 9 (2005) 198-206
45. Nelson R., and Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev (2006) CD003770
46. Kemeny N., Huang Y., Cohen A.M., Shi W., Conti J.A., Brennan M.F., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341 (1999) 2039-2048
47. Kemeny N.E., and Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 352 (2005) 734-735
48. Kemeny N., Jarnagin W., Gonen M., et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 21 (2003) 3303-3309
49. House MG, Kemeny N, Jarnagin WR, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer [abstract 383]. 2009 Gastrointestinal Cancers Symposium, ASCO. 2009.
50. Kemeny N., Eid A., Stockman J., et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 91 (2005) 97-101
51. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23 (2005) 4881-4887
52. Lang E.K., and Brown Jr. C.L. Colorectal metastases to the liver: selective chemoembolization. Radiology 189 (1993) 417-422
53. Sanz-Altamira P.M., Spence L.D., Huberman M.S., et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 40 (1997) 770-775
54. Martinelli D.J., Wadler S., Bakal C.W., et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 74 (1994) 1706-1712
55. Hunt T.M., Flowerdew A.D., Birch S.J., Williams J.D., Mullee M.A., and Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 77 (1990) 779-782
56. Tellez C., Benson III A.B., Lyster M.T., et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82 (1998) 1250-1259
57. 90yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 48 (2001) 333-337
58. Gray B.N., Burton M.A., Kelleher D.K., Anderson J., and Klemp P. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol 42 (1989) 192-196
59. 166Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig. Nucl Med Commun 15 (1994) 545-553
60. Van Hazel G., Blackwell A., Anderson J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88 (2004) 78-85
61. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25 (2007) 1099-1106
62. van Hazel G.A., Pavlakis N., Goldstein D., et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27 (2009) 4089-4095
63. Nicolay N.H., Berry D.P., and Sharma R.A. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 6 (2009) 687-697
64. Wereldsma J.C., et al. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 65 (1990) 425-432
65. Beart Jr. R.W., et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 125 (1990) 897-901
66. Allen-Mersh T.G., et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344 (1994) 1255-1260
67. Elias D., et al. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg 180 (1995) 213-219
68. Link K.H., et al. Regional chemotherapy of non-resectable liver metastases from colorectal cancer--literature and institutional review. Langenbecks Arch Surg 384 (1999) 344-353
69. Meric F., et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7 (2000) 490-495
70. Milandri C., et al. Combined treatment of inoperable liver metastases from colorectal cancer. Tumori 89 Suppl (2003) 112-114
71. Mancuso A., et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 23 (2003) 1917-1922
72. Noda M., et al. Second-look hepatectomy after pharmacokinetic modulating chemotherapy (PMC) combination with hepatic arterial 5FU infusion and oral UFT in patients with unresectable hepatic colorectal metastases. J Clin Oncol (Meeting Abstracts) 22 Suppl (2004) 3739
73. Selzner N., et al. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg 93 (2006) 587-592
74. Tono T., and Monden T. The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer. Nippon Geka Gakkai Zasshi 101 (2000) 568-573
75. Lygidakis N.J., et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 48 (2001) 1685-1691